Clinical Trial Update: Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating olverembatinib in chronic myeloid leukemia in chronic phase patients who failed at least two prior second-generation TKIs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Olverembatinib (Olverembatinib)

Snippet

Sponsor: Shenzhen Second People's Hospital | Conditions: Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 3 | Status: UNKNOWN